The massive market transformation this month that some on Wall Street called a "once in a decade opportunity" might have just been a one-off technical move because of taxes.Marketsread more
The Pentagon will deploy U.S. forces to the Middle East on the heels of the attack on Saudi Arabian oil facilities, United States Secretary of Defense Mark Esper announced...Defenseread more
CNBC did a deep dive through the most recent Wall Street research to find stocks that analysts say are underappreciated.Marketsread more
Shares of MasterCard are up 46% this year, and 1120% since 2011, getting a boost from the strong U.S. consumer.Investingread more
CNBC sat in on an "empathy training" at Amazon PillPack's Somerville offices, which is part of new hire orientation.Technologyread more
Trade with China is the 'big unknown' for the Federal Reserve as it decides how best to support the U.S. economy, says Council on Foreign Relations Director of International...Futures Nowread more
Lobbying experts said the visit is likely an attempt to be in lawmakers' ears as they consider legislation that would impact Facebook.Technologyread more
Yardeni Research's Edward Yardeni believes the U.S. economy is picking up steam.Trading Nationread more
Iran's audacious drone and cruise missile attack on Saudi Arabia's oil producing facilities has provided a critical test yet for the Trump administration's foreign policy. A...Politicsread more
Chinese trade negotiators suddenly canceled a visit to meet U.S. farmers after they wrapped up trade talks in Washington this week.Marketsread more
Depomed announced on Friday that a U.S. District Court ruled in favor of the company in a patent case for NUCYNTA, its long-acting opioid drug for chronic pain.
The specialty pharmaceutical company had filed a patent infringement claim against Actavis, Alkem Laboratories, Roxane Laboratories and their affiliates. The defendant companies had filed abbreviated new drug applications for Depomed's NUCYNTA franchise.
As of this ruling, the company said it now expects market exclusivity for NUCYNTA ER, NUCYNTA and NUCYNTA oral solution until Dec. 2025.
"We are pleased with the Court's decision as it confirms the validity and strength of the NUCYNTA patents," said Jim Schoeneck, president and CEO of Depomed. "We look forward to growing the NUCYNTA franchise, comprised of two important and highly-differentiated medicines, for at least the next 9 years."
The stock had spiked as much as 13 percent before paring its gains to about 4.5 percent prior to being halted for news pending at 3:17 p.m. ET. The stock resumed trading at 4:20 p.m. ET and were last about 3 percent higher in after-hours trade.